The Drug-price Transparency for Consumers Act of 2025 adds a new section to Title XI of the Social Security Act requiring direct-to-consumer advertisements for prescription drugs and biological products to include pricing information. The disclosure centers on the wholesale acquisition cost (WAC) for a 30-day supply or a typical course of treatment, and includes an allowance to explain variations due to insurance coverage.
A public reporting mechanism and civil penalties for noncompliance are also established, with final regulations due within one year and a phased implementation deadline.
At a Glance
What It Does
The bill directs HHS to require that DTC ads for prescription drugs and biologicals include an appropriate pricing disclosure, focusing on the WAC for a 30-day supply or typical course. It creates an exemption for drugs with a WAC under $35 per 30-day supply and sets rulemaking to implement the disclosure across advertising formats.
Who It Affects
Pharmaceutical manufacturers, advertising agencies, media networks, and health plans that run or sponsor DTC ads; consumers who view those ads, including Medicare/Medicaid beneficiaries and private plan enrollees.
Why It Matters
Pricing disclosures in ads could shift consumer expectations, enable price comparisons, and affect demand signals to manufacturers. The measure targets the lack of price transparency in drug advertising and seeks to align marketing with more informed purchasing decisions.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new requirement to direct-to-consumer advertising for prescription drugs and biological products, mandating an explicit disclosure of the product’s price based on its wholesale acquisition cost. The disclosure must reflect a 30-day supply or a typical course of treatment, and it may note that the out-of-pocket cost may differ depending on a consumer’s insurance coverage.
To prevent exemptions from being exploited to dodge price information, the act sets a standard ($35 WAC threshold) for exemptions to the rule. The implementation timeline requires final regulations within one year and sets July 1, 2026 as the target date by which the disclosure must appear in qualifying ads.
The act also authorizes penalties for noncompliance and creates a mechanism for public reporting to aid enforcement.
The Five Things You Need to Know
The bill adds a new Section 1150D to Title XI requiring price disclosures in DTC advertisements for prescription drugs and biological products.
Pricing information must be the Wholesale Acquisition Cost (WAC) for a 30-day supply or typical course, with an explanation that actual costs may vary by insurance.
Drugs with a 30-day WAC under $35 are exempt from the disclosure requirement.
Final regulations must be issued within one year, detailing visuals, audio, and update timing for price disclosures.
Civil penalties may reach up to $100,000 per violation, and the government may use reporting data to enforce compliance.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Pricing disclosure requirement for DTC advertisements
The bill adds a standalone requirement to include pricing information in direct-to-consumer ads for prescription drugs and biologicals that are paid for under title XVIII or XIX. It ties the disclosure to the drug’s Wholesale Acquisition Cost (WAC) for a 30-day supply or, where applicable, a typical course of treatment. The section also sets the stage for exemptions and the regulatory framework that will define how the information is presented across media.
General requirement
Under the general requirement, the Secretary must ensure that ads include the pricing disclosure described in this provision. This establishes the baseline mechanism by which price information becomes a formal, required element of DTC marketing for most federally covered drugs.
Pricing disclosure contents
The disclosure must clearly state the wholesale acquisition cost for a 30-day supply or typical course and may note that actual out-of-pocket costs depend on insurance coverage. This aligns consumer expectations with the price signal that drives affordability discussions and formulary decisions.
Rulemaking
The Secretary is instructed to issue final regulations within one year after enactment. These regulations will specify the visual and auditory standards and the timeframe for updating price disclosures when WAC changes occur, ensuring consistency across all ad formats.
Sanctions
Noncompliance can result in civil penalties of up to $100,000 per violation. The penalties follow the framework of the existing penalties regime under the broader context of the Social Security Act and related enforcement authorities.
Public reporting
The Secretary may use information from manufacturers that fail to comply to enforce the requirement, creating a public-facing incentive structure for advertisers to adhere to the new disclosure rules.
Definitions
Key terms include: Biblical definitions of 'biological product' and 'prescription drug' aligned with FDA and PHSA definitions; and 'wholesale acquisition cost' as defined for pricing disclosures.
Authorization of appropriations
The bill authorizes appropriations as necessary to carry out the section, ensuring funding for rulemaking, enforcement, and related activities.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare and private plan beneficiaries who face high out-of-pocket costs, as price visibility can inform treatment decisions and budget planning.
- Private health plans and employers sponsoring self-insured or employer-sponsored plans, which may realize downstream cost-containment from price transparency.
- Consumer advocacy groups and patient organizations that aim to empower patients with price information to compare options and negotiate affordability.
- Healthcare providers who can reference explicit pricing signals in counseling patients about treatment choices and cost considerations.
Who Bears the Cost
- Pharmaceutical manufacturers that advertise brand-name drugs and provide pricing disclosures to comply with the new requirement.
- Direct-to-consumer advertising agencies and media buyers responsible for integrating pricing disclosures into campaigns and ensuring timely updates.
- Regulatory agencies (CMS/HHS) that will administer rulemaking, monitoring, and enforcement efforts, which may require additional staffing and systems.
- Some health plans and payers may bear administrative costs associated with aligning marketing materials to the new disclosures and supporting consumer education.
Key Issues
The Core Tension
The central tension is between transparent price signals that empower consumer choice and the risk that such disclosures could distort pricing incentives or mislead about actual costs faced by patients, particularly where insurance coverage and rebates distort posted WAC.
The bill’s approach embraces price transparency as a consumer information tool, but it raises implementation questions. Defining the optimal way to present WAC in varied media formats (TV, online, print) without overwhelming viewers will require careful design in the forthcoming regulations.
The $35 exemption threshold means many lower-cost drugs will avoid disclosures, which could skew perceptions of overall drug pricing. Additionally, the policy relies on WAC as a price signal, which may not align with actual patient costs after rebates, coupons, and insurance design.
Enforcement will also hinge on the robustness of reporting mechanisms and the administrative capacity of federal agencies.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.